Ipilimumab 10 and 3 mg/kg in Canadian tertiary cancer centers.

Trial Profile

Ipilimumab 10 and 3 mg/kg in Canadian tertiary cancer centers.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2014

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jul 2014 New trial record
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top